OTC Sedative Effects Subject Of FDA/NTSB Meeting In November
This article was originally published in The Tan Sheet
Executive Summary
Data gathered at a November meeting on potential transportation risks associated with the use of sedating medicines by vehicle operators could bolster support for an FDA-mandated OTC switch of second-generation antihistamines.
You may also be interested in...
OTC Sedation Warning Effectiveness To Be Considered By FDA/NTSB
The inability of consumers to recognize they have impaired motor skills after taking potentially sedating OTC antihistamines likely will be discussed at a joint FDA/National Transportation Safety Board meeting Nov. 14-15
OTC Sedation Warning Effectiveness To Be Considered By FDA/NTSB
The inability of consumers to recognize they have impaired motor skills after taking potentially sedating OTC antihistamines likely will be discussed at a joint FDA/National Transportation Safety Board meeting Nov. 14-15
OTC Sedation Warning Effectiveness To Be Considered By FDA/NTSB
The inability of consumers to recognize they have impaired motor skills after taking potentially sedating OTC antihistamines likely will be discussed at a joint FDA/National Transportation Safety Board meeting Nov. 14-15